STARLUX signs order for ten more Airbus A350-1000 aircraft

Bruno Even Chief Executive Officer Airbus Helicopters Airbus SE
Bruno Even Chief Executive Officer Airbus Helicopters - Airbus SE
0Comments

Paris, France – STARLUX Airlines, based in Taiwan, has finalized a purchase agreement with Airbus for ten additional A350-1000 aircraft. The deal was formalized at the Paris Airshow by STARLUX Airlines CEO Glenn Chai and Benoît de Saint-Exupéry, Airbus EVP Sales of the Commercial Aircraft business.

Currently, STARLUX Airlines operates a fleet of 28 all-Airbus aircraft including models such as the A350-900, A330neo, and A321neo. The airline also has an existing order for 30 more aircraft including A350F freighters and A350-1000s.

Glenn Chai stated that expanding their international fleet with more A350-1000s is a strategic move to enhance global presence and market connectivity. “This aircraft offers efficiency, range and comfort,” he said. “As we continue to strengthen our international network, the A350-1000 will play an important role in driving growth, sustainability and operational flexibility.”

Benoît de Saint-Exupéry commented on STARLUX Airlines’ decision as reinforcing the standing of the A350-1000 as a benchmark for long-haul operations. He noted its advanced design and fuel-efficient performance which allow airlines to optimize routes while reducing environmental impact. “We are pleased to strengthen our long-standing partnership with STARLUX Airlines,” he added.

The Airbus A350 is recognized for setting new standards in intercontinental travel due to its modern design and efficiency. It can fly up to 9,700 nautical miles non-stop using 25% less fuel compared to previous generations. Additionally, it is equipped to operate with up to 50% Sustainable Aviation Fuel (SAF), with plans for full SAF capability by 2030.

Globally, the A350 Family has received over 1,390 orders from 60 customers worldwide. Currently, more than 650 of these aircraft are active within fleets across 38 operators mainly on long-haul routes.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.